Biosimilar Remicade now available in Europe
This article was originally published in Scrip
The privately owned company, Alvogen, has launched Inflectra, a biosimilar version of Janssen's Remicade, in eight central and eastern EU markets. The product is being marketed under a strategic partnership with the US firm Hospira, which in turn has an agreement with the biosimilar's originator, South Korea's Celltrion.
You may also be interested in...
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.